Day One Biopharmaceuticals, Inc. (DAWN)
Apr 21, 2026 - DAWN was delisted (reason: acquired by Servier)
21.53
+0.04 (0.19%)
Inactive · Last trade price on Apr 22, 2026

DAWN Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
158.18131.16---
Revenue Growth
20.60%----
Cost of Revenue
17.215.28---
Gross Profit
140.97125.88---
Selling, General & Admin
120.59115.4575.5461.2929.16
Research & Development
148.14222.7130.5285.6243.58
Operating Expenses
268.72338.15206.06146.9172.74
Operating Income
-127.75-212.27-206.06-146.91-72.74
Interest & Investment Income
18.4719.717.194.750
Other Non Operating Income (Expenses)
-0.02109.22-0.04-0.02-0.02
EBT Excluding Unusual Items
-109.3-83.35-188.92-142.18-72.75
Other Unusual Items
--5---
Pretax Income
-109.3-88.35-188.92-142.18-72.75
Income Tax Expense
-1.987.14---
Earnings From Continuing Operations
-107.32-95.5-188.92-142.18-72.75
Minority Interest in Earnings
----2.11
Net Income
-107.32-95.5-188.92-142.18-70.65
Preferred Dividends & Other Adjustments
----99.99
Net Income to Common
-107.32-95.5-188.92-142.18-170.64
Net Income Growth
-----
Shares Outstanding (Basic)
10393806537
Shares Outstanding (Diluted)
10393806537
Shares Change
10.70%16.87%21.85%77.13%568.42%
EPS (Basic)
-1.04-1.02-2.37-2.17-4.62
EPS (Diluted)
-1.04-1.02-2.37-2.17-4.62
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-104.08-80.28-147.08-109.9-48.54
Free Cash Flow Per Share
-1.01-0.86-1.84-1.68-1.31
Gross Margin
89.12%95.97%---
Operating Margin
-80.76%-161.84%---
Profit Margin
-67.85%-72.81%---
Free Cash Flow Margin
-65.80%-61.21%---
EBITDA
-124.27-210.71-206.03-146.85-72.72
EBITDA Margin
-78.56%-160.65%---
D&A For EBITDA
3.481.560.040.060.02
EBIT
-127.75-212.27-206.06-146.91-72.74
EBIT Margin
-80.76%-161.84%---
Revenue as Reported
158.18131.16---
SEC Filings: 10-K · 10-Q